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STATE OF MAINE
CUMBERLAND, ss.

SUPERIOR COURT
CIVIL ACTION

DONNA HEADRICK and STEVEN' - - y
RIDLON, on behalf of themselves and all
)
others similarly situated,
)
)
Plaintiffs,
)
)
v.
) DOCKET NO. CV-99-148
)
F. HOFFMANN-LAROCHE, LTD., et al,
)
)
Defendants.
)
)
/

STATE OF MAINE
HANCOCK, ss.

SUPERIOR COURT
CIVIL ACTION

ERIN B. SEMBA, on behalf of herself and all )
others similarly situated,
)
)
Plaintiff,
)
)
) DOCKET NO. CV-99-50
v.
)
LONZA AG, et al,
)
)
Defendants
)
)
ORDER APPROVING
SETTLEMENT AND FINAL JUDGMENT
This Court, having considered Plaintiffs’ motion for final approval of the Amended
Maine Settlement Implementing Agreement and the Master Settlement Agreement (“MSA”),
entered into on behalf of Plaintiffs and the Settlement Classes by Plaintiffs’ Lead Counsel
1
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(“PLC”), the State of Maine by the Maine Attorney General, and the Settling Defendants by their
respective counsel; and having entered an order on July 21, 2001, preliminarily approving the
Settlement and conditionally certifying the following settlement classes:
' (a)
a Maine Consumer Settlement Class consisting of all natural
persons (excluding the Released Parties) who purchased Indirect Vitamin
Products for use or consumption by themselves and/or others and not for resale in
any form, and who: (i) were residents of Maine as of October 10, 2000, and (ii)
purchased Indirect Vitamin Products from within one or more of the Settling
States at any time during the Relevant Period; and
(b)
a Maine Commercial Settlement Class consisting of all persons or
entities (excluding Government Entities and the Released Parties) that made a
Maine Qualifying Purchase during the Relevant Period;
and due notice having been published and given to the Maine Settlement Classes of the proposed
settlement and of a hearing scheduled to determine whether the proposed settlement should be
approved as fair, reasonable, and adequate and to hear any objections to any of these matters (the
“Fairness Hearing”); and having given all persons an opportunity to request exclusion from the
Settlement; having excluded those who filed valid requests for exclusion; having given all class
members with objections to the Settlement an opportunity to present such objections to the
Court; and having held the Fairness Hearing and considered the submissions and arguments
made in connection with the motion for final approval of the settlement; IT IS ORDERED,
ADJUDGED AND DECREED THAT:
I. DEFINITIONS
1.

Terms used in this Order that are defined in the Amended Maine Settlement

Implementing Agreement, the MSA, or the Order for Preliminary Approval of Partial Settlement
are used here as defined therein, unless otherwise specified.

?
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IL JURISDICTION
2.

The Settling Defendants, the Plaintiffs, and the Maine Settlement Classes have

submitted to the jurisdiction of the Court for purposes of enforcing the Amended Maine
Settlement Implementing Agreement. The Court has personal jurisdiction for purposes of
enforcing and administering the settlement over the Settling Defendants, the Plaintiffs, and the
Maine Settlement Classes, and subject matter jurisdiction to approve the Amended Maine
Settlement Implementing Agreement with respect to the Maine Settlement Classes.
IH. NOTICE TO CLASS AND APPLICABILITY
3.

Notice to the Maine Settlement Classes has been given in an adequate, reasonable,

and sufficient manner and constitutes the best notice practicable, complying in all respects with
applicable Maine law and the requirements of due process. The notice given to the members o f
the Maine Settlement Classes was reasonably calculated under the circumstances to inform the
Maine Settlement Classes of the pendency of the actions involved in this case, of ail material
elements of the proposed settlement, and of their opportunity to exclude themselves from, object
to, or comment on the settlement and to appear at the Fairness Hearing. Members of the Maine
Settlement Classes were given full opportunity to participate in the Fairness Hearing.
Accordingly, the Court determines that all members of the Maine Settlement Classes are bound
by this Order Granting Final Approval of Partial Settlement and Final Judgment.
IV. CERTIFICATION OF SETTLEMENT CLASS
4.

For settlement purposes, class certification is an appropriate method for protecting

the interests of the members of the Maine Settlement Classes and for resolving the common
issues of fact and law arising out of the alleged violations of the Maine’s antitrust and consumer
->
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protection laws. On July 20, 2001, this Court conditionally certified the Maine Consumer and
Commercial Settlement Classes for settlement purposes. The Maine Settlement Classes continue
to satisfy the applicable standard for class certification, making final class certification for
settlement purposes appropriate.
5.

The Court finds for the purposes of settlement only that the requirements of

Maine Rule of Civil Procedure 23 have been satisfied.
6.

For settlement purposes, the Court also finds Plaintiffs’ Lead Counsel and the

other Maine Class Counsel, to be adequate and competent class counsel.
7.

Accordingly, the Court makes final its certification of the Maine Settlement

Classes for settlement purposes only.
8.

Provided, however, that all persons and/or entities Jj&vT-have filed a valid request

for exclusion, and those allowed to opt out by order of this Court, shall be excluded from the
Settlement.
V. FINAL APPROVAL OF PARTIAL CLASS SETTLEMENT
9.

The Court has held a hearing to consider the fairness, reasonableness, and

adequacy of the proposed settlement, has been advised of any objections thereto, and has given
fair consideration to such objections.
10.

PLC,
IT

C

, the Settling States, and the Settling Defendants, negotiated

the settlement at arm’s length and in good faith.
11.

The Settling Parties have complied with all material terms of the Court’s July 20,

2001 Order for Preliminary Approval of Partial Settlement.
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12.

The proposed settlement, being in all respects fair, reasonable, adequate and

proper and in the best interests of thé Maine Settlement Classes, given the benefits of settlement
and the risks, complexity, expense, and probable duration of further litigation between the State
of Maine, Maine Settlement Classes and the Settling Defendants, is accordingly finally
APPROVED.
VL APPROVAL OF PLAN OF DISTRIBUTION
13.

In order to promote efficiency and fairness, and eliminate unnecessary complexity

from the claims process, the Court finds the multistate plan of distribution to combine the Maine
Commercial Settlement Amount with other Settling States’ Commercial Settlement Amounts, for
distribution among all valid claimants from all Settling States, based on each claimant's pro rata
share of the total Vitamin Content Dollars on all validated Proofs of Claim, to be fair, reasonable,
adequate, and in the best interests of the Maine Commercial Settlement Class.
14.

The Commercial Settlement Class multistate plan of distribution is, accordingly,

hereby APPROVED. The Maine Commercial Settlement Amounts in the amount of $ 333,050 is
hereby allocated to the Commercial Class Settlement Escrow Account to be administered by the
ADR Court for distribution (minus approved costs and expenses) on a multistate basis to all
eligible Commercial Settlement Class members who submitted a valid Proof of Claim, including
Maine Commercial Settlement Class members.
15.

Due to the impracticability of identifying particular injured consumers of Indirect

Vitamin Products during the Relevant Period and the high costs of administering a direct cash
distribution to millions of Maine individual consumers relative to the average likely award to
those consumers, the Court finds that a cy pres distribution administered by the Maine Attorney
5
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General to eligible organizations for the express purpose of ensuring the fund be used for the
improvement of the health and/or nutrition of the citizens of Maine and/or the advancement of
nutritional, dietary or agricultural science in Maine is fair, reasonable, and adequate and in the
best interests of the Maine Consumer Settlement Class.
16.

The Maine Plan of Distribution for the Consumer Class Settlement Amount and

the SEIF is adjudged fair, reasonable, and adequate and is APPROVED. The Maine Attorney
General is directed to cause the settlement funds to be distributed in accordance with the Plan o f
Distribution.
VH. DISMISSAL OF ACTION AND RELEASE OF CLAIMS
17.

All Maine Consumer Settlement Class members’ claims against the Settling

Defendants and any Released Parties that are defendants (the "Dismissed Parties") are hereby
dismissed with prejudice.
18.

AJ1 Maine Commercial Settlement Class members’ claims against Settling

Defendants and any Dismissed Parties are hereby dismissed with prejudice.
19.

The Released Parties shall be released and forever discharged from all manner o f

claims, demands, actions, suits and causes of action, whether class, individual or otherwise in
nature; damages whenever incurred; liabilities of any nature whatsoever, including costs,
expenses, penalties and attorneys’ fees, known or unknown, suspected or unsuspected, in law or
equity, that any member of the Maine Settlement Classes, on their own behalf or on behalf of
their present and former officers, directors, agents, employees, legal representatives, trustees,
parents, affiliates, subsidiaries, heirs, executors, administrators, purchasers, predecessors,
successors and assigns, (the “Maine Class Action Releasing Parties"), or the Maine Attorney
6
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General, on behalf of the State of Maine and any person or entities (including government
entities) acting in a parens patriae, sovereign, quasi-sovereign, private attorney general, qui tam,
taxpayer, or any other capacity, whether or not any of them participate in this settlement, to the
extent that any such person or entity is seeking relief on behalf of or generally applicable to the
general public in Maine or the people of Maine (the “Maine State Releasing Parties”), whether
directly, representatively, derivatively or in any other capacity, ever had, now have or hereafter
can, shall or may have, relating in any way to any conduct prior to the date hereof concerning the
purchase, sale or pricing of Vitamin Products, including, without limitation, any such claims
which have been asserted or could have been asserted against the Released Parties or any one of
them (the “Released Claims”), provided, however, that such release shall not affect the rights of
any Maine Class Action Releasing Party to pursue a claim for a California Purchase, or to pursue
a claim under the Sherman Act (15 U.S.C. § 1 et. ssq.) based on sales directly invoiced by any
Released Party to a Maine Class Action Releasing Party, and provided further that such release
shall not release any claims set forth in paragraph V.A.2 of the Master Settlement Agreement
(which claims have been released pursuant to a separate agreement).
20.

The foregoing releases shall not release any product liability or breach of contract

claims unrelated to the subject matter of the Maine Class Actions.
21.

No member of the Maine Settlement Classes shall hereafter be permitted in any

suit, action or proceeding to seek to establish liability of any kind against any Released Party on
any Released Claim.
22.

In addition to the provisions of paragraphs 19, 20, and 21 each Maine Class

Action Releasing Party and each Maine State Releasing Party hereby expressly agrees that it will
7
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waive and release, with respect to the Released Claims that have been released pursuant to
paragraph 19 any, and all provisions, rights and benefits conferred by any law of any state or
territory of the United States, or principle of common law which provides in substance that “a
general release does not extend to claims which the creditor does not know or suspect to exist in
his favor at the time of executing the release, which if known by him must have materially
affected his settlement with the debtor.” Each Maine Class Action Releasing Party and each
Maine State Releasing Party acknowledges that it may hereafter discover facts other than or
different from those that it knows or believes to be true with respect to the subject matter of the
Released Claims that have been released by such party pursuant to paragraph 19, but each Maine
Class Action Releasing Party and each Maine Releasing Party shall hereby be deemed to have
waived and fully, finally and forever settled and released any known or unknown, suspected or
unsuspected, contingent or non-contingent claim with respect to the Released Claims that such
Maine Class Action Releasing Party or Maine State Releasing Party has released pursuant to
paragraphs 19, 20, and 21, whether or not concealed or hidden, without regard to the subsequent
discovery or existence of such different or additional facts.
23.

Nothing in this Order, the MSA, or the Amended Maine Settlement Implementing

Agreement and no aspect of the settlement is or shall be deemed or construed to be an admission,
concession or evidence of any violation of any statute or law or of any liability or wrongdoing by
any Released Party, or of the truth of any of the claims or allegations contained in the complaints
or any other pleadings any action related to the subject matter of the Released Claims, or of the
propriety of certifying a class of any direct or indirect purchasers of Vitamin Products other than,
for settlement purposes only, the Settlement Classes, and evidence thereof shall not be
8
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discoverable or used, directly or indirectly, in any way, including in any action relating to the
subject matter of the Released Claims or in any other action or proceeding.
Y in . FEES AND COSTS
24.

The Court approves up to $ 34,704 for the payment of notice, claims

administration, expert and other costs related to this case and for securing approval of the
Settlement, to be deducted from the Maine Consumer Settlement Amount. The Court notes that
while a final summary of expenses for the Maine Settlement Classes shall be submitted for
approval by PLC, Maine Class Counsel, and the Maine Attorney General at a later time, the
amount to be deducted for costs and expenses from the Maine Consumer Settlement Class
Amount shall not exceed $34,704.00.
25.

Separate from, and in addition to, the settlement amounts set forth above, the

Settling Defendants have agreed to pay, subject to court approval and the terms of the MSA,
Class Counsel’s attorneys’ fees in an amount not to exceed 16.67 % of the sum of such fees plus
the total class settlement amounts. That is, the attorneys’ fees cannot exceed 16.67% of the total
amount of the Settling Defendants’ settlement payments, including the attorneys’ fees portion.
See MSA § ED . Counsel will provide separate documentation for this request when the final
expense summaries are filed and the Court reserves ruling on Class Counsels’ petitions for
attorneys’ fees until that time.
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coordination with suits in other jurisdictions require it, the Court finds good cause to waive the
time limits imposed by M.R.Civ.P. 54(b)(3) and hereby relieves counsel from compliance with
them. Counsel shall file their final expense summaries and petitions for fees in a reasonable
time.
9
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X. FINALITY OF JUDGMENT
26.

There is no just reason for delay of entry of a final judgment of dismissal with

prejudice as to the Settling Defendants and all Released Parties that are Defendants, and the
Clerk is therefore directed to enter final judgment pursuant to M.R.Civ.P. 54(b), 58 and 79(a) on
the docket of these cases. This Court finds that, with the exception of costs and attorneys’ fees,
this Order and Final Judgment adjudicates all the claims, rights, and liabilities of the Maine
Settlement Classes and the Settling Defendants, and is final.
XL RETENTION OF JURISDICTION
27.

Without affecting the finality of this Order and Judgment, the Court retains

jurisdiction for the purposes of enforcing the terms of the Amended Maine Settlement
Implementing Agreement and enabling any of the Settling Parties to apply to this Court at any
time for such further orders and directions as may be necessary and appropriate for the
construction or carrying out of this Order and Final Judgment and the enforcement of compliance
with this Order and Final Judgement. For all matters for which the Court retains jurisdiction, the
Settling Defendants and the members of the Maine Settlement Classes are deemed to have
irrevocably waived any claim that they are not subject to the jurisdiction of this Court or that this
Court is in any way an improper venue or an inconvenient forum.
28.

Pursuant to the terms of the Amended Maine Settlement Implementing

Agreement and paragraphs IX.F and IX. G of the MSA, jurisdiction for the purposes of
administering the Commercial Settlement Escrow Account for the Maine Commercial Settlement
Classes and the determination of all issues relating to the Commercial Settlement Class portion
of the settlement, shall be vested in the ADR Court. This Court retains jurisdiction for the
10
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purposes of determining issues relating to the Maine Consumer Settlement Class, administration
of the Maine Consumer Class Settlement Escrow Accounts, and awarding final expenses and
attorneys’ fees.
IT IS ORDERED, this

Y "day of

-

Superior Court Justice
2 1 8\H:\CLIENTS\HEADRICK\VITAM IN\heaorder3.pld
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STATE OF MAINE
CUMBERLAND, SS.

SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-99-148
zoQz o c i a r

a

& 48

DONNA HEADRICK and STEVEN
RIDLON, on behalf of themselves and all
Others similarly situated in Maine,
Plaintiffs,
and
THE STATE OF MAINE, BY THE
ATTORNEY GENERAL, on behalf of
Maine Residents,
Intervenor-Plaintiff
v.
F. HOFFMAN-LAROCHE, LTD., et al.,
Defendants

)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)

STATE OF MAINE
HANCOCK, ss.

SUPERIOR COURT
CIVIL ACTION
DOCKET NO. CV-99-50

ERIN B. SEMBA, on behalf of herself and all
others similarly situated,

)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)

Plaintiff,
and
THE STATE OF MAINE, BY THE
ATTORNEY GENERAL, on behalf of
Maine Residents,

v.

Intervenor-Plaintiff
'

LONZAAG, etal.,
Defendants

ORDER ON MOTION TO AMEND MAINE PLAN OF DISTRIBUTION FOR
CONSUMER CLASS SETTLEMENT AMOUNT AND STATE ECONOMIC IMPACT
FUND

Having considered the request of the Attorney General and no objections having been
filed, this Court hereby GRANTS the Attorney General’s Motion to Amend Maine Plan of
Distribution for Consumer Class Settlement Amount and State Economic Impact Fund.

It is hereby ORDERED:
The Maine Plan of Distribution for Consumer Class Settlement Amount and State
Economic Impact Fund is AMENDED consistent with the attached amended Plan.

Dated:

JUSTICE, SUPERIOR COURT

Ik)

MAINE PLAN OF DISTRIBUTION
FOR CONSUMER CLASS SETTLEMENT AMOUNT
AND STATE ECONOMIC IMPACT FUND
Amended September 20021

The State of Maine proposes that its pro rata share of the Distribution
(approximately $1,245 million) be distributed to six entities. We believe that each of
these organizations will effectively use this money to comply with the terms of the
settlement agreement by benefiting the targeted group of injured consumers, and will
improve the health and nutrition of a large number of Maine citizens.
The proposed distributions to promote "health and/or nutrition" in Maine [Master
Settlement Agreement § VI.E.4(b)] were selected by the Maine Attorney General, in
consultation with Plaintiffs' Lead Counsel in this case.
The Maine Attorney General will exercise its discretion under section VI.E.6 of
the Master Settlement Agreement to allocate its entire State Economic Impact Fund
("SEIF") amount of $116,000 to its Consumer Class Escrow Account, in recognition of
the economic harm that consumers in Maine may have suffered as a result of the
defendants' alleged conduct. This allocation will bring the total settlement funds
allocated to the Consumer Class Escrow Account to approximately $1,361 million. All
of these funds will then be distributed in accordance with the "Distribution of the
Consumer Class Settlement Account" provisions of the Master Settlement Agreement, §
VI.E.4.
1.

Maine Area Agencies on Aging

$105,000

Maine’s 5 Area Agencies on Aging will provide one-time grants to community/

1Amended language italicized.

neighborhood organizations or municipalities. The grants will increase the availability of
services related to physical or mental health in which services, such as transportation to
and from doctors’ appointments. This project will largely assist elderly people who wish
to remain in their homes.
2.

Maine School Food Service Association
a)

School Breakfast Subsidy

$360,000

This money will enable schools to offer breakfast to a greater number of students. There
are 730 schools in Maine where 99,197 lunches but only 25,253 breakfasts are served
each week. Studies have shown that school breakfasts enhance student’s attention,
improve behavior, and reduce visits to the nurse’s office.
b)

School Food Service/Maine Farmers Conference

$3,000

This conference will link school food service personnel with local farmers, and encourage
schools to buy directly from farmers, thus improving the quality of food purchased by
schools.
c)

Scholarships for Food Service Personnel

$50,000

Funds will be used to train food service personnel in nutrition, sanitation, and cost
effective management. Currently, most food service personnel are not able to take
advantage of training opportunities because of lack of funds.
3.

March of Dimes

$265,000

Funds will be used to provide education to women of child-bearing age, and to
supplement existing programs that supply multivitamins with folic acid. Only 35% of
Maine women age 18-44 consume a vitamin or supplement containing folic acid, which is
an important way to prevent birth defects. The goal of this statewide program is to

decrease the incidence of birth defects.
4.

Maine Bureau of Health and the Maine Nutrition Network

$286,500

The Bureau of Health will collaborate with the Maine Nutrition Network, a statewide
coalition of over 200 partners established by the University of Southern Maine’s Edmund
5. Muskie School of Public Service, Institute for Public Sector Innovation. The funds
will build on and expand the Maine Nutrition Network’s past efforts which targeted food
stamp recipients only. This statewide nutrition and physical activity campaign will
improve the overall health of all people in Maine, regardless of socio-economic status.
5.

Maine Department of Agriculture Food Assistance Program and Community

Action Programs

$131,500

This money will be used to install a refrigerator/freezer at the Department of
Agriculture’s warehouse that stores food for the voluntary feeding programs throughout
Maine, such as soup kitchens, food pantries, food banks, and temporary shelters. This
will increase the warehouse’s capacity for perishable food products and improve the
quality of food and nutrition available to low-income families. The money will also be
used to pay other storage costs on donated surplus commodities that are received from
the federal government, stored in warehouses and distributed to Community Action
Programs.
6.

Maine Senior FarmShare Program

$160,000

This program links low-income seniors with locally grown produce. Seniors and
organizations providing meals and food to low-income seniors are eligible to purchase
“shares” from local farmers. This funding will increase the number of low-income
seniors and farmers involved.

SUPERIOR COURT OF THE DISTRICT OF COLUMBIA
CIVIL DIVISION

)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
on behalf of themselves and all
)
others similarly situated in the District of )
Columbia, Alabama, Arizona,
)
California, Florida, Kansas, Maine,
)
Michigan, Minnesota, New Mexico,
)
New York, North Carolina, North Dakota, )
South Dakota, Tennessee, West Virginia,
) and Wisconsin,
)
)
Plaintiffs,
)
)
vs.
)
)
F. HOFFMANN-LAROCHE, LTD.,
)
HOFFMANN-LAROCHE, INC., ROCHE )
VITAMINS, INC., RHONE-POULENC
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EISAI CO., LTD., EISAI U.S.A., INC.,
EISA! INC., TAKEDA CHEMICAL
INDUSTRIES, LTD., TAKEDA
VITAMIN & FOOD U.S.A., INC.,
TAKEDA U.S.A., INC., MERCK KgaA,
E. MERCK, and EM INDUSTRIES, INC.
Defendants.

)
)
)
)
)
)
)
)

___________________________________________ )
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ADDRESS LIST OF DEFENDANTS
F. Hoffrnann-LaRoche, Ltd.
Box CH-4070
Basel, SWITZERLAND
Hoffrnann-LaRoche, Inc.
340 Kingsland St.
Nutley, NJ 07110
Roche Vitamins, Inc.
206 Roche Dr.
Belvidere, NJ 07832
Rhone-Poulenc Animal Nutrition, Inc.
500 Northridge Rd.
Atlanta, GA 30350
Rhone-Poulenc, S.A.
25, quai Paul Doumer
92408 Courbevoie Cedex, FRANCE
BASF A.G.
Carl-Bosch-StraPe 38
67056 Ludwigshafen, GERMANY
BASF Corporation
3000 Continental Drive North
Mount Olive, NJ 07828
Lonza A.G.
Munchensteinerstrasse 38
P.O. Box CH 4002
Basel, SWITZERLAND
Lonza Inc.
17-17 Route 208
Fairlawn, NJ 07410
Chinook Group, Ltd.
40 Allison Avenue
Morrisbrg, ON KOCIXO
Ontario, CANADA
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Chinook Group, Inc.
41420 Forest Blvd.
Box 290
North Branch, MN 55056
DuCoa, L.P.
115 Executive Drive
Highland, IL 62249
John Kennedy
c/o Chinook Group Inc.
4119 White Bear Pkwy #200
White Bear Lake, MN 55110
Robert Samuelson
c/o Chinook Group Inc.
4119 White Bear Pkwy #200
White Bear Lake, MN 55110
Lindell Hilling
546 Troy Ofallon Road
Troy, IL 62294-2930
J. L. “Pete” Fisher
c/o DuCoa L. P.
115 Executive Dr.
PO Box 219
Highland, IL 62249
Antonio Felix
c/o DuCoa L. P.
115 Executive Dr.
PO Box 219
Highland, IL 62249
Eisai Co., Ltd.
4-6-10 Koishikawa, Bunkyo-ku
Tokyo 112-88, JAPAN
Eisai U.S.A., Inc.
Marathon Oil Tower, Suite 690
5555 San Felipe Road
Houston, TX 77056

Eisai Inc.
Glenpointe Centre West, 5th Floor
500 Frank W. Burr Boulevard
Teaneck, NJ 07666-6741
Takeda Chemical Industries, Ltd.
1-1, Doshomachi 4-chome,
Chuo-ku, Osaka 541-8645 JAPAN
Takeda Vitamin & Food U.S.A., Inc.
101 Takeda Drive
Wilmington, NC 28401
Takeda U.S.A., Inc.
8 Corporate Drive
Orangeburg, NY 10962-2614
Merck KgaA
Frankfurter Strasse 250
64293 Darmstadt, GERMANY
E. Merck
Frankfurter Strasse 250
64293 Darmstadt, GERMANY
EM Industries, Inc.
7 Skyline Drive
Hawthorne, NY 10532
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Plaintiffs Teresa Herminia Giral, Horace Robertson, Philip Richardson, Ila Z.
McLaughlin, Herbert Pardell, Heman Diaz-Bolano, Manuel De La Fuente, Carolyn Garofolo,
Candace Todd, Donna Headrick, Anthony Bascomb, Denise Denardi, Amy L. Currens, William
G. Scanlan, Tina L. Nicholson, Rita D. O’Neill, Kirk Chafee, Walter B. McCampbell, Jr., Gary
E. Archer, William B. McGinley, J&R Ventures, Inc., and Kristen Westlake by and through their
undersigned attorneys, bring this action on behalf of themselves and all others similarly situated
in the District of Columbia, Alabama, Arizona, California, Florida, Kansas, Maine, Michigan,
Minnesota, New Mexico, New York, North Carolina, North Dakota, South Dakota, Tennessee,
West Virginia, and Wisconsin (“the Class Jurisdictions”) for damages and declaratory and
injunctive relief under the antitrust, consumer protection, and common laws of the Class
Jurisdictions against the above-named Defendants. For their Complaint against Defendants,
Plaintiffs, upon personal knowledge as to their own acts and status, and upon information and
belief as to all other matters, allege the following:
I.
1.

INTRODUCTION

This case arises out of a massive and long-running international conspiracy

beginning no later than 1989, and continuing until at least September 1998, among all
Defendants and their co-conspirators with the purpose and effect of fixing prices, allocating
market share, and committing other unlawful practices designed to inflate the prices of vitamins,
vitamin premixes, bulk vitamins, and other vitamin products sold to Plaintiffs and other
purchasers in the District of Columbia and the other Class Jurisdictions.
2.

Defendants’ conspiracy has involved an astonishing array of illegal conduct by an

international cartel that has deliberately targeted, and severely burdened, consumers in the
6

District of Columbia and the other Class Jurisdictions. The conspiracy has existed at least during
the period from 1989 to September 1998, and has affected billions of dollars of commerce
involving products found in nearly every American household. The conspiracy has included
communications and meetings in which Defendants agreed expressly and repeatedly to eliminate
competition, injure and destroy businesses that would have reduced Defendants’ illegal market
control, and fix the prices and allocate markets for vitamins A, B, C, D, E, H, vitamin premixes,
bulk vitamins, and other vitamin products.
3.

The charged combination and conspiracy consisted of a continuing agreement,

understanding, and concert of action among Defendants and their co-conspirators, the substantial
terms of which were:
a.

to fix, stabilize, and maintain prices, and to coordinate price increases, for
the sale of vitamins, vitamin premixes, bulk vitamins, and other vitamin
products in the District of Columbia and the other Class Jurisdictions;

b.

to allocate among the corporate Defendants and their co-conspirators the
volume of sales of vitamins, vitamin premixes, bulk vitamins, and other
vitamin products in the District of Columbia and the other Class
Jurisdictions;

c.

to allocate among the corporate Defendants and their co-conspirators all or
part of certain contracts to supply vitamins, vitamin premixes, bulk
vitamins, and other vitamin products to various customers located in the
District of Columbia and the other Class Jurisdictions.

d.

to refrain from submitting bids, or to submit collusive, non-competitive,
and rigged bids to supply vitamins, vitamin premixes, bulk vitamins, and
other vitamin products to various customers located in the District of
Columbia and the other Class Jurisdictions; and

e.

to supply vitamins, vitamin premixes, bulk vitamins, and other vitamin
products to various customers located throughout the District of Columbia
and the other Class Jurisdictions at non-competitive prices and receive
compensation therefrom.
7

4.

The acts in furtherance o f the conspiracy by Defendants have included the

follow ing wrongful conduct and horizontal agreements:

a.

participating in meetings and conversations throughout the Class
Jurisdictions and elsewhere, in which Defendants and their co-conspirators
discussed and agreed concerning the prices, volume of sales, and markets
for vitamins and vitamin premixes, including for vitamins B-3 (niacin and
niacinamide) and B-4 (choline chloride). Executives participating in the
illegal meetings and discussions concerning vitamins B-3 and B-4 include
John Kennedy, Robert Samuelson, Lindell Hilling, J. L. “Pete” Fisher, and
Antonio Felix;

b.

agreeing, during those meetings and conversations, to charge prices at
specified levels and otherwise increase and maintain prices of vitamins B3 (niacin and niacinamide) and B-4 (choline chloride) sold in the District
of Columbia and the other Class Jurisdictions;

c.

agreeing, during those meetings and conversations, to allocate among the
corporate Defendants and their corporate co-conspirators the approximate
volume of B-3 (niacin and niacinamide) and B-4 (choline chloride) to be
sold by each corporate conspirator in the District of Columbia and the
other Class Jurisdictions;

d.

agreeing, during those meetings and conversations, to allocate among the
corporate Defendants and their corporate co-conspirators customers of B-3
(niacin and niacinamide) and B-4 (choline chloride) in the District of
Columbia and the other-Class Jurisdictions;

e.

agreeing, during those meetings and conversations, to restrict B-3 (niacin
and niacinamide) and B-4 (choline chloride) producing capacity among
the corporate Defendants and co-conspirators;

f.

exchanging sales and customer information for the purpose of monitoring
and enforcing adherence to the above-described agreements;

g.

issuing price announcements and price quotations in accordance with the
agreements reached;

h.

discussing among co-conspirators the submission of prospective bids to
supply B-3 (niacin and niacinamide) and B-4 (choline chloride) to
customers located in the District of Columbia and the other Class
Jurisdictions;
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5.

i.

designating which corporate conspirator would be the designated low
bidder for contracts to supply B-3 (niacin and niacinamide) and B-4
(choline chloride) to customers located in the District of Columbia and the
other Class Jurisdictions;

j.

discussing and agreeing upon prices to be contained within the bids for
contracts to supply B-3 (niacin and niacinamide) and B-4 (choline
chloride) to customers in the District of Columbia and the other Class
Jurisdictions;

k.

refraining from bidding or submitting intentionally high, complementary
bids for the contracts to supply B-3 (niacin and niacinamide) and B-4
(choline chloride) to customers in the District of Columbia and the other
Class Jurisdictions;

l.

supplying B-3 (niacin and niacinamide) and B-4 (choline chloride) to
various customers in the District of Columbia and the other Class
Jurisdictions at non-competitive prices and receiving compensation
therefrom.

A sa result of their illegal activities, Defendants Lonza AG, John Kennedy,

Robert Samuelson, Lindell Hilling, J. L. “Pete” Fischer, and Antonio Felix have pleaded guilty
to violating Section 1 of the Sherman Act, 15 U.S.C. § 1, by participating in a conspiracy to fix
prices and allocate the volume of sales of vitamins B-3 (niacin and niacinamide) and B-4
(choline chloride) in the United States.
6.

For purpose of forming and carrying out the charged combination and conspiracy,

Defendants and their co-conspirators, including executives from both United States and
European affiliates of Defendants, have also participated in numerous other meetings and
conversations, including:
a.

Meetings in the Black Forest in Germany in the 1990's, in which it was
agreed to allocate among the corporate conspirators the sales volumes and
markets for vitamins, vitamin premixes, bulk vitamins and other vitamin
products to be sold by each corporate conspirator in the District of
9

Columbia and the other Class Jurisdictions. The conspiracy divided and
allocated such markets by region and by vitamin and was implemented by
United States marketing managers acting under instructions from their
European supervisors. Executives participating in these meetings and
discussions include Wilhelm Tell, Edmund McDonald, Kuno Sommers
and Oscar Mendoza of the Roche Vitamins and Fine Chemicals Division;
and Lloyd Curtis, Vernon Schaefer, and Peter Haag of BASF, and others.
b.

A 1997 meeting in Atlanta, Georgia between a premix blender and
European executives of BASF at which the BASF executives told the
blender that it was competing in BASF markets and should get out of the
markets.

c.

At least two meetings in 1995 and 1996 in Ludwigshafen, Germany at
which BASF executives instructed brokers and distributors not to sell
vitamin A in the United States or they would be denied access to the raw
materials necessary to manufacture vitamin A.

d.

Secret meetings and discussions between executives of Roche, BASF and
Lonza in 1995 and 1996 wherein it was agreed that Lonza would control
the market for vitamin B-3/niacin with Roche as a customer and Lonza
would stop selling biotin/vitamin H.

e.

Meetings and discussions in which salespersons and executives of Roche
and Rhone-Poulenc told customers in the United States that they would
bid on only a percentage of a customer’s business and that their products
were not to be resold to poultry producers.

f.

Meetings and discussions in which BASF executives in Europe instructed
brokers and distributors not to sell choline chloride or face the prospect of
being driven out of business.

7.

In furtherance of the illegal combination and conspiracy alleged herein,

Defendants also engaged in numerous other acts, practices, and courses of conduct including:
a.

Jointly agreeing to engage in “denied access marketing” by setting the
prices of vitamin components of vitamin premixes higher collectively than
the price of premixes as a means to implement and protect the horizontal
conspiracy. Through this strategy, the conspiracy used its control over the
inputs and vitamin components to drive premixers and blenders out of
business who threatened the conspiracy’s power to control outputs and
supply in the premix markets. For example, a secret 1991 BASF business
10

report expressly described the pricing of “straights in premixes” to be
offered to implement this denied access marketing strategy. This denied
access marketing strategy was implemented by, among others, United
States executives for BASF acting at the direction of BASF officials in
Germany. The purpose of this marketing strategy was to eliminate the
market for component vitamin purchases of premixes, with the result that
the horizontal conspiracy would control over 90 percent of the markets for
vitamin premixes, markets which are allocated among the members of the
conspiracy. Indeed, a BASF business plan from 1993 or 1994, for
example, states the conspiracy’s intent to end competition by small premix
blenders leaving the conspiracy with control of over 90% of the vitamin
premix market.
b.

Roche and BASF reallocated business from Roche to BASF after a
customer gave its exclusive business to Roche;

c.

A BASF business plan from 1993 or 1994 sets forth the conspiracy’s
intent to end competition by small premix blenders leaving the conspiracy
with control of over 90% of the vitamin premix market;

d.

Purchasing manufacturing plants and facilities and forming joint ventures
throughout the world to control the supply and markets for vitamins,
including a 1997 joint venture Roche Taishan (Shanghai) Vitamin
Products and two 1997 joint ventures in Xinghuo, China for the
production of vitamins E and A. Roche has also purchased and shutdown
vitamin A and vitamin E facilities in Shanghai to control the output of
these vitamins pursuant to the terms of the conspiracy.

e.

Issuing price announcements in publications and coordinating price
quotations to customers in accordance with the agreements reached.

II.
8.

JURISDICTION AND VENUE

Plaintiffs bring this civil action pursuant to the District of Columbia Restraints of

Trade Act, D.C. Code §§ 28-4501 etseq. and the Consumer Protection Procedures Act, D.C.
Code §§ 28-3901 et seq. Jurisdiction is conferred upon this Court by D.C. Code §§ 11-921, 13423, 28-3905,28-4508 and 28-4509.
9.

This action is also commenced on behalf of indirect purchasers of the Defendants’
11

vitamin products in each of the Class Jurisdictions, pursuant to the following antitrust and
consumer protection laws of the respective jurisdictions:
Alabama:

Ala. Code §§6-5-60 and 8-10-1

Arizona:

A.R.S. §44-1402, etseq.

California:

Cal. Bus & Prof. Code §§ 16720, 16726 and 16750
Cal. Bus & Prof. Code § 17200, et seq.

Florida:

Florida Statutes §501.204, etseq.

Kansas:

Kan. Stat. Ann. § 50-101, et seq.
Kan. Stat. Ann. §50-626(b)

Maine:

10 M.R.S.A. §1101, etseq.
5 M.R.S.A. §207

Michigan

M.C.L.A. § 445.772, etseq.
M.C.L.A. § 19.418(3)

Minnesota

Minn. Stat. Ann §§ 325D.57 and 325D.58
Minn. Stat. Ann. §325D.44

New Mexico:

N.M. Stat. Ann. §57-1-3
N.M. Stat. Ann. §57-12-3

New York:

N.Y. Gen. Bus. § 340, et seq.

North Carolina

N.C. Gen. Stat. §75-1, etseq.

North Dakota:

N.D. Cent. Code §51-08.1-08
N.D. Cent. Code §51-15-02

South Dakota:

S.D. Codified Laws Ann. §§37-1-14.3, 37-1-33
S.D. Codified Laws Ann. §37-26-6

Tennessee:

Tenn. Code Ann. §§47-25-101, 47-25-105,
47-25-106
Tenn. Code Ann. §47-18-104
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West Virginia

W. Va. Code §47-18-1, etseq.
W. Va. Code §46A-6-104 and §47-11 A-1, etseq.

Wisconsin:

Wis. Stat. § 133.01, et seq.
Wis. Stat. Ann. §100.18(1)

10.

Without limiting the generality of the foregoing, the Defendants (directly or

through agents who were at the time acting with actual and/or apparent authority and within the
scope of such authority) have:
a.

transacted business in each of the Class Jurisdictions;

b.

contracted to supply or obtain services or goods in in each of the Class
Jurisdictions;

c.

intentionally availed themselves of the benefits of doing business in each
of the Class Jurisdictions;

d.

produced, promoted, sold, marketed and/or distributed their products or
services in each of the Class Jurisdictions and, thereby, have purposefully
profited from their access to the markets in each of the Class Jurisdictions;

e.

caused tortious damage by act or omission in each of the Class
Jurisdictions;

f.

caused tortious damage in each of the Class Jurisdictions by acts or
omissions committed outside such jurisdictions while (i) regularly doing
or soliciting business in such jurisdictions, and/or (ii) engaging in other
persistent courses of conduct within such jurisdictions and/or (iii) deriving
substantial revenue from goods used or consumed or services rendered in
such jurisdictions;

g.

committed acts and omissions which Defendants knew or should have
known would cause damage (and, in fact, did cause damage) in each of the
Class Jurisdictions to the Plaintiff and members of the Class while (i)
regularly doing or soliciting business in such jurisdictions, and/or (ii)
engaging in other persistent courses of conduct within such jurisdictions
and/or (iii) deriving substantial revenue from goods used or consumed or
services rendered in such jurisdictions; and

h.

otherwise had the requisite minimum contacts with each of the Class
13

Jurisdictions, such that, under the circumstances, it is fair and reasonable
to require the Defendants to come to this Court to defend this action.
11.

Venue is proper in this jurisdiction pursuant to D.C. Code §§ 11-921, 13-423, 28-

3905, 28-4508 and 28-4509. Plaintiff Teresa Giral is a resident of the District of Columbia and,
in addition, a substantial part of the trade and commerce, as well as the arrangement, contract,
agreement, trust, combination, conspiracy, unfair or deceptive practices, and/or uniform and
common course of conduct giving rise to Plaintiffs’ claims, occurred within the District of
Columbia, including, among other things, the sale of vitamins, vitamin premixes, and other
vitamin products to Plaintiffs and other members of the Class at supra-competitive prices.
12.

As a result of the manufacture, distribution, delivery and sale of the Defendants’

products to purchasers within the District of Columbia, directly or through their subsidiaries,
affiliates or agents, Defendants obtained the benefits of the laws of the District of Columbia and
the District of Columbia market for their products.
13.

The total amount in controversy as to each Plaintiff and each individual member

of the Class alleged herein does not exceed seventy-four thousand dollars ($74,000.00), even if
trebled, exclusive of interest and costs, and Plaintiffs do not seek any form of “common”
recovery. Further, Plaintiffs and the Class assert no federal question or statute, and Plaintiffs’
state law causes of action are not federally pre-empted. Plaintiffs state, and intend to state,
causes of action solely under the laws District of Columbia and the other Class Jurisdictions and
specifically deny any attempt to state a cause of action under the laws of the United States of
America.
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III.
A.

PARTIES

Plaintiffs
14.

Plaintiff Teresa Herminia Giral is a resident of the District of Columbia. Plaintiff

Giral is an indirect purchaser of vitamins, vitamin premixes, or other vitamin products
manufactured by one or more of the Defendants.
15.

Plaintiff Horace Robertson is an individual with his principal place of business

in Cullman County, Alabama. Plaintiff Robertson purchases vitamins manufactured by one or
more of the defendants for personal use and for use in his farming operations.
16.

Plaintiff Philip Richardson is a resident of Maricopa County, Arizona. Plaintiff

Richardson is an indirect purchaser of vitamins, vitamin premixes, or other vitamin products
manufactured by one or more of the Defendants.
17.

Plaintiff Ila Z. McLaughlin is a resident of San Francisco County, California.

Plaintiff McLaughlin is an indirect purchaser of vitamins, vitamin premixes, or other vitamin
products manufactured by one or more of the Defendants.
18.

Plaintiffs Manuel De La Fuente and Heman Diaz-Bolano are residents of Dade

County, Florida. Plaintiffs De La Fuente and Diaz-Bolano are indirect purchasers of vitamins,
v itam in

premixes, or other vitamin products manufactured by one or more of the Defendants.
19.

Plaintiff Herbert Pardell is a resident of Broward County, Florida. Plaintiff

Pardell is an indirect purchaser of vitamins, vitamin premixes, or other vitamin products
manufactured by one or more of the Defendants.
20.

Plaintiff Carolyn Garofolo is a resident of Dade County, Florida. Plaintiff

Garofolo is an indirect purchaser of vitamins, vitamin premixes, or other vitamin products
15

manufactured by one or more o f the Defendants.

21.

Plaintiff Candace Todd is a resident of Wyandotte County, Kansas. Plaintiff

Todd is an indirect purchaser of vitamins, vitamin premixes, or other vitamin products
manufactured by one or more of the Defendants.
22.

Plaintiff Donna Headrick is a resident of Portland, Maine. Plaintiff Headrick is an

indirect purchaser of vitamins, vitamin premixes, or other vitamin products manufactured by one
or more of the Defendants.
23.

Plaintiff Anthony Bascomb is a resident of Oakland County, Michigan. Plaintiff

Bascomb is an indirect purchaser of vitamins, vitamin premixes, or other vitamin products
manufactured by one or more of the Defendants.
24.

Plaintiff Denise Denardi is an individual with her residence in Mendota Heights,

Minnesota. Plaintiff Denardi is an indirect purchaser of vitamins, vitamin premixes, or other
vitamin products manufactured by one or more of the Defendants.
25.

Plaintiff Amy L. Currens is a resident of Bernalillo County, New Mexico.

Plaintiff Currens is an indirect purchaser of vitamins, vitamin premixes, or other vitamin
products manufactured by one or more of the Defendants.
26.

Plaintiff William G. Scanlan is a resident of Albany County, New York. Plaintiff

Scanlan is an indirect purchaser of vitamins, vitamin premixes, or other vitamin products
manufactured by one or more of the Defendants.
27.

Plaintiff Tina Nicholson is a resident of Charlotte, North Carolina. Plaintiff

Nicholson is an indirect purchaser of vitamins, vitamin premixes, or other vitamin products
manufactured by one or more of the Defendants.
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28.

Plaintiff Rita O’Neill is a resident of Bismarck, North Dakota. Plaintiff O’Neill is

an indirect purchaser of vitamins, vitamin premixes, or other vitamin products manufactured by
one or more of the Defendants.
29.

Plaintiff Kirk Chafee is a resident of Meade County, South Dakota. Plaintiff

Chafee is an indirect purchaser of vitamins, vitamin premixes, or other vitamin products
manufactured by one or more of the Defendants.
30.

Plaintiff Walter B. McCampbell Jr. is a resident of Jefferson County, Tennessee.

Plaintiff McCampbell is an indirect purchaser of vitamins, vitamin premixes, or other vitamin
products manufactured by one or more of the Defendants.
31.

Plaintiff Gary E. Archer is a resident of Charleston, West Virginia. Plaintiff

Archer is an indirect purchaser of vitamins, vitamin premixes, or other vitamin products
manufactured by one or more of the Defendants.
32.

Plaintiff William B. McGinley is an individual with a residence in Ripley, West

Virginia. Plaintiff McGinley is an indirect purchaser of vitamins, vitamin premixes, or other
vitamin products manufactured by one or more of the Defendants.
33.

Plaintiff J&R Ventures, Inc. (formerly known as Professional Products &

Services, Inc.) is a Wisconsin corporation with its principal place of business in Prairie du Sac,
Wisconsin. Plaintiff is an indirect purchaser of vitamins, vitamin premixes, or other vitamin
products manufactured by one or more of the Defendants.
34.

Plaintiff Kristen Westlake is a resident of Milwaukee County, Wisconsin.

Plaintiff Westlake is an indirect purchaser of vitamins, vitamin premixes, or other vitamin
products manufactured by one or more of the Defendants.
17

B.

D e fe n d a n ts

35.

Defendant F. Hoffmann-LaRoche, Ltd. (“Roche Ltd.”) is a Swiss corporation with

operations in the United States. Roche Ltd. is a subsidiary of Roche Holding Ltd., a Swiss
pharmaceutical company based in Basel, Switzerland. Roche Ltd., through its affiliates, is
engaged in the business of the distribution and sale of vitamins, vitamin premixes and/or bulk
vitamin products in the District of Columbia and the other Class Jurisdictions. Roche Ltd.,
directly and through affiliates that it dominates and controls, has set prices pursuant to illegal
horizontal agreements to fix, maintain, or stabilize prices of vitamins, vitamin premixes, and bulk
vitamin products, and these horizontal pricing practices were designed to have, and in fact did
have, a substantial and adverse impact within the District of Columbia and the other Class
Jurisdictions.
36.

Defendant Hoffmann-LaRoche, Inc. (“Roche Inc.”) is a New Jersey corporation

with its principal place of business in Nutley, New Jersey. Roche Inc. is an affiliate of Roche
Ltd. and is wholly-controlled and dominated by Roche Ltd., both with respect to the conduct of
its business within the United States generally and specifically with respect to the
anticompetitive conduct alleged herein within the District of Columbia and the other Class
Jurisdictions. Roche Inc. was directly engaged in the business of the distribution and sale of
vitamins, vitamin premixes and bulk vitamin products in the District of Columbia and the other
Class Jurisdictions until at least 1997.
37.

Defendant Roche Vitamins, Inc. (“Roche Vitamins”) is a Delaware coiporation

with its principal place of business in Parsippany, New Jersey. Roche Vitamins is whollycontrolled and dominated by Roche Ltd., both with respect to the conduct of its business within
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the United States generally and specifically with respect to the anticompetitive conduct alleged
herein within the District of Columbia and the other Class Jurisdictions. Roche Vitamins is
directly engaged in the business of the distribution and sale of vitamins, vitamin premixes and
bulk vitamin products throughout the District of Columbia and the other Class Jurisdictions.
Roche Ltd., Roche Inc., and Roche Vitamins are hereinafter referred to as “Roche.”
38.

Defendant Rhone-Poulenc S.A. (“RP S.A.”) is a French corporation with

operations in the United States. RP S.A., through its affiliates, is engaged in the business of the
distribution and sale of vitamins, vitamin premixes and bulk vitamin products in District of
Columbia and the other jurisdictions. RP S.A., directly and through affiliates that it dominates
and controls, has set prices pursuant to illegal horizontal agreements to fix, maintain, or stabilize
prices of vitamins, vitamin premixes, and bulk vitamin products, and these horizontal pricing
practices were designed to have, and in fact did have, a substantial and adverse impact within the
District of Columbia and the other Class Jurisdictions.
39.

Defendant Rhone-Poulenc Animal Nutrition, Inc. (“RP Animal Nutrition”) is a

Delaware corporation with its principal place of business in Atlanta, Georgia. RP Animal
Nutrition is wholly-controlled and dominated by RP S.A. with respect to the conduct of its
business within the United States generally and specifically with respect to the anticompetitive
conduct alleged herein within the District of Columbia and the other Class Jurisdictions. RP
Animal Nutrition is a successor to Rhone-Poulenc, Inc. (“RP Inc.”), a New York corporation.
RP Inc. was engaged in the business of the distribution and sale of vitamins, vitamin premixes,
and bulk vitamin products in the District of Columbia and the other Class Jurisdictions until at
least 1996. Since at least 1996, RP Animal Nutrition has been engaged in the business of the
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distribution and sale of vitamins, vitamin premixes and bulk vitamin products throughout the
District of Columbia and the other Class Jurisdictions. RP S.A., RP Inc., and RP Animal
Nutrition are hereinafter referred to as “Rhone-Poulenc.”
40.

Defendant BASF A.G. is a German corporation with operations in the United

States. BASF A.G., through its affiliates, is engaged in the business of the distribution and sale
of vitamins, vitamin premixes and bulk vitamin products throughout the District of Columbia
and the other Class Jurisdictions. BASF A.G., directly and through its United States affiliates
that it controls, and through actions in this country and outside the United States, has set prices
pursuant to illegal horizontal agreements to fix, maintain, or stabilize prices of vitamins, vitamin
premixes, and bulk vitamin products, and these horizontal pricing practices were designed to
have, and in fact did have, a substantial and adverse impact within the District of Columbia and
the other Class Jurisdictions.
41.

Defendant BASF Corporation is a Delaware corporation with its principal place of

business in Mount Olive, New Jersey. BASF Corporation is engaged in the business of the
distribution and sale of vitamins, vitamin premixes and bulk vitamin products throughout the
District of Columbia and the other Class Jurisdictions. BASF Corporation is a wholly-owned
affiliate of BASF A.G. and is wholly-controlled and dominated by BASF A.G., both with respect
to the conduct of its business within the United States generally and specifically with respect to
the anticompetitive conduct alleged herein within the District of Columbia and the other Class
Jurisdictions. Defendants BASF A.G. and BASF Corporation are hereinafter referred to as
“BASF.”
42.

Defendant Lonza, Inc. is a New York corporation with its principal place of
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business in Fair Lawn, New Jersey. Lonza, Inc. is wholly-controlled and dominated by Lonza
A.G., both with respect to the conduct of its business within the United States generally and
specifically with respect to the anticompetitive conduct alleged herein in the District of Columbia
and the other Class Jurisdictions. Lonza, Inc. is engaged in the business of the distribution and
sale of vitamins, vitamin premixes, and bulk vitamins in the District of Columbia and the other
Class Jurisdictions.
43.

Defendant Lonza, AG is a corporation organized and existing under the laws of

Switzerland. Lonza, AG is a manufacturer of niacin and niacinamide, and through Lonza, Inc., is
engaged in the sale of vitamins, including niacin and niacinamide, in the District of Columbia
and the other Class Jurisdictions. Defendant Lonza, AG has pleaded guilty to violating Section 1
of the Sherman Act, 15 U.S.C. § 1, for conspiring to fix prices and allocate the volume of sales of
vitamin B-3 (niacin and niacinamide). Defendants Lonza, Inc. and Lonza A.G. are hereinafter
referred to as “Lonza.” Lonza has set prices pursuant to illegal horizontal agreements to fix,
maintain, or stabilize prices of vitamins, vitamin premixes, and bulk vitamin products, and these
horizontal pricing practices were designed to have, and in fact did have, a substantial and adverse
impact within the District of Columbia and the other Class Jurisdictions.
44.

Defendant Chinook Group, Ltd., headquartered in Toronto, Canada, is a limited

partnership that was formed in and is currently organized and existing under the laws of Ontario,
Canada. During the period of this Complaint, Chinook Group, Ltd. was a manufacturer of
choline chloride. Choline chloride is a vitamin of the B-complex group (Vitamin B-4). During
the period of this Complaint, Chinook Group, Ltd. was engaged in the sale of choline chloride in
the District of Columbia and the other Class Jurisdictions.
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45.

Defendant Chinook Group, Inc. is a Minnesota corporation with its principal place

of business in White Bear Lake, Minnesota. Defendant Chinook Group, Inc. is a wholly owned
subsidiary of Defendant Chinook Group, Ltd. In conjunction with Chinook Group Ltd., Chinook
Group Inc. is engaged in the sale of choline chloride throughout the District of Columbia and the
other Class Jurisdictions.
46.

Defendant John Kennedy is Vice President of Sales and Marketing for Defendant

Chinook Group Inc. Defendant Kennedy has pleaded guilty to violating Section 1 of the
Sherman Act, 15 U.S.C. § 1, by conspiring to fix prices and allocate customers and the sales of
vitamin B-4 (choline chloride).
47.

Defendant Robert Samuelson is a national sales manager for Defendant Chinook

Group Inc. Defendant Samuelson has pleaded guilty to violating Section 1 of the Sherman Act,
15 U.S.C. § 1, by conspiring to fix prices and allocate customers and the sales of vitamin B-4
(choline chloride). Defendants Chinook Ltd., Chinook Inc., Kennedy, and Samuelson are
hereinafter referred to as “Chinook.” Chinook has set prices pursuant to illegal horizontal
agreements to fix, maintain, or stabilize prices of vitamins, vitamin premixes, and bulk vitamin
products, and these horizontal pricing practices were designed to have, and in fact did have, a
substantial and adverse impact within the District of Columbia and the other Class Jurisdictions.
48.

Defendant DuCoa, L.P. is a joint venture between DuPont de Nemours and

Company (“DuPont”), a United States corporation with its principal place of business in
Wilmington, Delaware, and ConAgra, Inc., a United States corporation with its principal place of
business in Omaha, Nebraska. DuCoa, L.P.’s principal place of business is in Highland, Illinois
where it manufactures choline chloride. DuCoa, L.P. is engaged in the sale of choline chloride
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throughout th e D istric t o f C olum bia and the o ther C lass Jurisdictions.

49.

Defendant Lindell Hilling is the former President of Defendant DuCoa, L.P.

Defendant Hilling has pleaded guilty to violating Section 1 of the Sherman Act, 15 U.S.C. § 1,
by conspiring to fix prices and allocate customers and the sales of vitamin B-4 (choline chloride).
50.

Defendant J.L. “Pete” Fischer was employed initially as Manager, then as Vice

President and subsequently, beginning in January 1996, as the President, Basic Products and
International Division for Defendant DuCoa, L.P. Defendant Fischer has pleaded guilty to
violating Section 1 of the Sherman Act, 15 U.S.C. § 1, by conspiring to fix prices and allocate
customers and the sales of vitamin B-4 (choline chloride).
51.

Defendant Antonio Felix is Vice President, Basic Products and International

Division for Defendant DuCoa. Defendant Felix has pleaded guilty to violating Section 1 of the
Sherman Act, 15 U.S.C. § 1, by conspiring to fix prices and allocate customers and the sales of
vitamin B-4 (choline chloride). Defendants DuCoa, Samuelson, Fischer, and Felix are
hereinafter referred to as “DuCoa.” DuCoa has set prices pursuant to illegal horizontal
agreements to fix, maintain, or stabilize prices of vitamins, vitamin premixes, and bulk vitamin
products, and these horizontal pricing practices were designed to have, and in fact did have, a
substantial and adverse impact within the District of Columbia and the other Class Jurisdictions.
52.

Defendant Eisai Co., Ltd. (“Eisai Ltd.”) is a Japanese corporation with operations

in the United States. Eisai Ltd., through its affiliates, is engaged in the business of the
distribution and sale of vitamins, vitamin premixes, and other vitamin products in the District of
Columbia and the other Class Jurisdictions. Eisai Ltd., directly and through affiliates that it
dominates and controls, and through actions in this country and outside the United States, has set
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prices and allocated markets for vitamin E pursuant to illegal horizontal agreements, and these
horizontal practices were designed to have and in fact did have a substantial and adverse impact
within the District of Columbia and the other Class Jurisdictions.
53.

Defendant Eisai U.S.A. Inc. (“Eisai U.S.A.”) is a California corporation with its

principal place of business in Houston, Texas. Eisai U.S.A. is engaged in the business of the
distribution and sale of vitamins, vitamin premixes, and other vitamin products throughout the
District of Columbia and the other Class Jurisdictions. Eisai U.S.A. is a wholly-owned affiliate
of defendant Eisai Inc., which is a wholly-owned affiliate of defendant Eisai Ltd. Eisai U.S.A. is
wholly controlled and dominated by Eisai Ltd., both with respect to the conduct of its business
within the United States generally and specifically with respect to the anticompetitive conduct
alleged herein within the District of Columbia and the other Class Jurisdictions.
54.

Defendant Eisai Inc. is a Delaware corporation with its principal place of business

in Teaneck, New Jersey. Eisai, Inc. is engaged in the business of the distribution and sale of
vitamins, vitamin premixes, and other vitamin products throughout the District of Columbia and
the other Class Jurisdictions. Eisai Inc. is a wholly-owned affiliate of defendant Eisai Ltd., and
wholly owns defendant Eisai U.S.A. Eisai Inc. is wholly-controlled and dominated by Eisai Ltd,
both with respect to the conduct of its business within the United States generally and
specifically with respect to the anticompetitive conduct alleged herein within the District of
Columbia and the other Class Jurisdictions. Defendants Eisai Ltd., Eisai U.S.A. and Eisai Inc. are
hereinafter referred to as “Eisai.” Eisai has set prices pursuant to illegal horizontal agreements to
fix, maintain, or stabilize prices of vitamins, vitamin premixes, and bulk vitamin products, and
these horizontal pricing practices were designed to have, and in fact did have, a substantial and
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adverse im pact w ith in the D istric t o f C olum bia and the o ther C lass Jurisdictions.

55.

Defendant Takeda Chemical Industries, Ltd. (“Takeda Ltd.”) is a Japanese

corporation with operations in the United States. Takeda Ltd., through its affiliates, is engaged
in the business of the distribution and sale of vitamins, vitamin premixes, and other vitamin
products in the District of Columbia and the other Class Jurisdictions. Takeda Ltd., directly and
through affiliates that it dominates and controls, and through actions in this country and outside
the United States, has set prices and allocated markets for vitamin C pursuant to illegal
horizontal agreements, and these horizontal practices were designed to have and in fact did have
a substantial and adverse impact in the District of Columbia and the other Class Jurisdictions.
56.

Defendant Takeda Vitamin & Food U.S.A. (“Takeda Vitamin”) is a North

Carolina corporation with its principal place of business in Wilmington, North Carolina. Takeda
Vitamin is wholly-controlled and dominated by Takeda Ltd., both with respect to the conduct of
its business within the United States generally and specifically with respect to the
anticompetitive conduct alleged herein within the District of Columbia and the other Class
Jurisdictions. Takeda Vitamin is a successor to defendant Takeda U.S.A., Inc. (“Takeda
U.S.A.”), which prior to 1998 was engaged in the business of the distribution and sale of
vitamins, including vitamin C, throughout the District of Columbia and the other Class
Jurisdictions. During that period, Takeda U.S.A. was wholly-controlled and dominated by
Takeda Ltd., both with respect to the conduct of its business in the United States generally and
with respect to its challenged horizontal conduct within the District of Columbia and the other
Class Jurisdictions. Since at least 1998, Takeda Vitamin has been directly engaged in the
business of the distribution and sale of vitamins, including vitamin C, in the District of Columbia
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and the other Class Jurisdictions. Takeda Ltd., Takeda Vitamin, and Takeda U.S.A. are
hereinafter referred to as “Takeda.” Takeda has set prices pursuant to illegal horizontal
agreements to fix, maintain, or stabilize prices of yitamins, vitamin premixes, and bulk vitamin
products, and these horizontal pricing practices were designed to have, and in fact did have, a
substantial and adverse impact within the District of Columbia and the other Class Jurisdictions.
57.

Defendant Merck KgaA is a partnership organized under the laws of Germany

with operations in the United States. Merck KgaA, through its affiliates, is engaged in the
business of the distribution and sale of vitamins, vitamin premixes, and other vitamin products in
the District of Columbia and the other Class Jurisdictions. Merck KgaA is 74% owned by
defendant E. Merck, a German partnership which is engaged in the business of the distribution
and sale of vitamins, vitamin premixes, and other vitamin products in the District of Columbia
and the other Class Jurisdictions. Merck KgaA, directly and through affiliates that it dominates
and controls, and through actions in this country and outside the United States, has set prices and
allocated markets pursuant to illegal horizontal agreements, and these horizontal practices were
designed to have, and in fact did have, a substantial and adverse impact within the District of
Columbia and the other Class Jurisdictions.
58.

Defendant E. Merck is a partnership organized under the laws of Germany with

operations in the United States. E. Merck is engaged in the business of the distribution and sale
of vitamins, including vitamin C, in the District of Columbia and the other Class Jurisdictions.
E. Merck, directly and though affiliates that it dominates and controls, and through actions in this
country and outside the United States, has set prices and allocated markets pursuant to illegal
horizontal agreements, and these horizontal practices were designed to have, and in fact did have,
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a substantial and ad v erse im pact w ith in th e D istrict o f C olum bia and the o ther C lass
Jurisdictions.

59.

Defendant EM Industries, Inc. (“EM Industries”) is a New York corporation with

its principal place of business in Hawthorne, New York. EM Industries is a wholly-owned
subsidiary of defendant Merck KgaA. EM Industries is engaged in the business of the
distribution and sale of vitamins, vitamin premixes, and other vitamin products in the District of
Columbia and the other Class Jurisdictions. EM Industries is wholly-controlled and dominated
by Merck KgaA and E. Merck, both with respect to the conduct of its business within the United
States generally and specifically with respect to the anticompetitive conduct alleged herein
within the District of Columbia and the other Class Jurisdictions. Defendants Merck KgaA, E.
Merck and EM Industries are hereinafter referred to as “Merck.” Merck has set prices pursuant
to illegal horizontal agreements to fix, maintain, or stabilize prices of vitamins, vitamin
premixes, and bulk vitamin products, and these horizontal pricing practices were designed to
have, and in fact did have, a substantial and adverse impact within the District of Columbia and
the other Class Jurisdictions.
60.

The acts alleged in this Complaint as having been done by Defendants were

authorized, ordered, or done by their officers, agents, employees, or representatives, while
actively engaged in the management of Defendants’ business or affairs.
C.

Unnamed Co-Conspirators
61.

Various other persons and entities, the identities of which are presently unknown,

have participated as co-conspirators with Defendants in the violations of law alleged herein and
have performed acts and made statements in the District of Columbia, the other Class
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Jurisdictions, and elsewhere in furtherance thereof.
IV.
62.

CLASS ACTION ALLEGATIONS

This action is brought by Plaintiffs on behalf of themselves, and pursuant to

Super.Ct.Civ.R. 23, as representative of a class (the “Class”).
63.

The Class is defined as:

All persons or entities present in the District of Columbia, Alabama, Arizona,
California, Florida, Kansas, Maine, Michigan, Minnesota, New Mexico, New
York, North Carolina, North Dakota, South Dakota, Tennessee, West Virginia,
and Wisconsin who indirectly purchased vitamins, vitamin premixes, bulk
vitamins, and/or other vitamin products manufactured by any of the Defendants or
their co-conspirators from January 1, 1989 to the present. The class of indirect
purchasers of these products includes consumers and businesses who have
purchased vitamin products designed for human consumption and/or as an animal
nutritional supplement. Excluded from the class are all governmental entities,
Defendants and other manufacturers of vitamins, vitamin premixes, bulk vitamins,
and other vitamin products, and their respective subsidiaries and affiliates.
64.

The members of the Class are so numerous that joinder of all members is

impracticable. While the exact number of Class members is unknown to Plaintiffs at the present
time, due to the nature of the trade and commerce involved, Plaintiffs believe that the members
of the Class are so numerous and geographically dispersed as to render joinder of all Class
members in this action impracticable.
65.

There are questions of law and fact arising in this action which are common to

Plaintiffs and the members of the Class, including:
a.

whether Defendants and their co-conspirators combined, agreed, and
conspired among themselves to fix, maintain, or stabilize the prices of, and
allocate markets for, vitamins, vitamin premixes, bulk vitamins, and other
vitamin products;

b.

the existence and duration of the horizontal agreements alleged in this
Complaint to fix, maintain, or stabilize prices of, and allocate markets for,
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vitamins, vitamin premixes, bulk vitamins, and other vitamin products;

66.

c.

whether each Defendant was a member of, or participant in the contract,
combination and/or conspiracy alleged in this Complaint;

d.

whether Defendants and their co-conspirators took steps to conceal their
conspiracy from Plaintiffs and Class;

e.

whether, and to what extent, the conduct of Defendants and their co
conspirators caused injury to the business or property of Plaintiffs and the
Plaintiff Class; and, if so, the appropriate measure of damages;

f.

whether the agents, officers or employees of Defendants and their coconspirators participated in telephone calls and meetings in furtherance of
the conspiracy alleged herein;

g.

whether Plaintiffs and members of the Class are entitled to declaratory
and/or injunctive relief;

h.

whether the acts and omissions alleged herein constitute an unlawful trust
or combination under the laws of the Class Jurisdictions;

i.

whether Defendants are properly within the scope of this Court’s
jurisdiction;

j.

whether the purpose and/or effect of the acts and omissions alleged herein
was to fix, raise, maintain, and/or stabilize the prices for vitamins, vitamin
premixes, bulk vitamins-, and other vitamin products sold or distributed in
the Class Jurisdictions;

k.

whether the unlawful combination and conspiracy alleged herein included
the allocation of sales volume among the Defendants; and

l.

whether the unlawful combination and conspiracy alleged herein involved
some or all of the vitamins described in this Complaint; and if so, which
ones.
Plaintiffs* claims are typical of the claims of the Class, because among other

reasons, Plaintiffs and all the Class members sustained damages in the same way, arising out of
the same wrongful conduct engaged in by the Defendants.
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67.

Plaintiffs will fully and adequately protect the interests of Class members.

Plaintiffs have retained counsel experienced in complex class actions, antitrust, and unfair or
deceptive trade practice litigation. Plaintiffs have no interests which are adverse to or in conflict
with other members of the Class.
68.

The questions of law and fact which are common to Plaintiffs and all members of

the Class predominate over any questions solely affecting individual members. Without limiting
the generality of the foregoing, the legal and factual issues concerning the existence, scope,
effects, and composition of the conspiracy alleged herein are (a) central to each plaintiffs claim,
(b) substantially identical with respect to each plaintiffs burden of demonstrating liability, and
(c) the most important and fundamental issues to be determined at trial.
69.

The class action mechanism is the superior, if not the only, available method for

the fair and efficient adjudication of this controversy. Proceeding as a class action would permit
the large number of injured parties to prosecute their common claims in a single forum
simultaneously, efficiently, and without unnecessary duplication of evidence and effort. A class
action is also the only practical way to avoid the potentially inconsistent results that numerous
individual trials are likely to generate. Moreover, class treatment is the only realistic means by
which plaintiffs with relatively small individual claims can effectively litigate against these large,
well-represented corporate Defendants. Numerous repetitive individual actions would also place
an enormous burden on the courts as they are forced to take duplicative evidence and decide the
same issues over and over again.
70.

There are no unusual difficulties likely to be encountered in the management of

this case as a class action and Plaintiffs and their counsel are not aware of any reason why this
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case should not proceed as a class action.
V.
71.

TRADE AND COMMERCE

Defendants are manufacturers, marketers, and distributors of vitamins (synthetic

and natural, and in dry and oil form), vitamin premixes, bulk vitamins (or “straights”) and other
vitamin products for sale to customers in the Class Jurisdictions and elsewhere. Defendants are
engaged in the sale, marketing, and distribution of vitamins, vitamin premixes, bulk vitamins,
and other vitamin products to manufacturers and users of animal feed and nutrition products.
The vitamin premixes and other vitamin products manufactured by Defendants are commonly
used in the agricultural industry as an ingredient in animal nutrition products and animal feed
mixes, as well as for consumption by domesticated animals and pets.
72.

Defendants are also engaged in the sale, marketing, and distribution of vitamins,

vitamin premixes, bulk vitamins and other vitamin products to manufacturers and distributors of
vitamin products designed for human consumption. Such vitamin products are purchased and
consumed by millions of consumers in the Class jurisdictions each year.
73.

The vitamins, vitamin premixes, bulk vitamins, and other vitamin products of

Defendants are sold in the District of Columbia and the other Class Jurisdictions. Roche sells in
the Class Jurisdictions vitamin A (acetate and palmatate), vitamin B, vitamin C, vitamin D,
vitamin E (D-Alpha and DL-Alpha), pantothenic acid, folic acid, riboflavin, beta carotene and
biotin. BASF sells in the Class Jurisdictions vitamin A (acetate and palmatate), vitamin C,
vitamin E (D-Alpha and DL-Alpha), vitamin B2, folic acid, riboflavin, and beta carotene.
Rhone-Poulenc sells in the Class Jurisdictions vitamin A (acetate and palmatate), vitamin B 12,
vitamin D3 and vitamin E (D-Alpha and DL-Alpha). Roche, BASF and Rhone-Poulenc together
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control over 95 percent of the worldwide markets for vitamins A and E. Defendant Lonza sells
in the Class Jurisdictions vitamin B-3 (niacin and niacinamide). Defendant DuCoa sells in the
Class Jurisdictions vitamin B-4 (choline chloride). Defendant Chinook sells in the Class
Jurisdictions vitamin B-4 (choline chloride).
74.

The manufacture of vitamins, vitamin premixes, bulk vitamins, and other vitamin

products is a multi-billion dollar a year industry worldwide. The North American market for
animal nutrition alone is over $500 million per year. The international conspiracy alleged herein
has affected billions of dollars of commerce involving vitamin products found in nearly every
American household, including billions of dollars of commerce in the District of Columbia and
the other Class Jurisdictions.
75.

The conduct of Defendants and their co-conspirators has directly, substantially

and foreseeably restrained the trade and commerce in the District of Columbia and the other
Class Jurisdictions.
VI.
A.

FACTUAL BACKGROUND

Violations of the Antitrust and Consumer Protection Laws
76.

Beginning no later than 1989, Defendants and their co-conspirators entered into

and actively engaged in a combination and conspiracy to suppress competition by fixing the price
and allocating the markets and sales volumes of vitamins, vitamin premixes, bulk vitamins, and
other vitamin products offered for sale to customers in the District of Columbia and the other
Class Jurisdictions. The combination and conspiracy engaged in by the Defendants and their co
conspirators was an unreasonable restraint of trade in violation of the District of Columbia
Restraints of Trade Act and Consumer Protection Procedures Act and the antitrust and consumer
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protection statutes of the other Class Jurisdictions.
77.

The acts committed by Defendants as alleged herein violate the antitrust statutes

and consumer protection statutes of the District of Columbia and the other Class Jurisdictions.
Specifically, Defendants illegally:

78.

a.

created or carried out restrictions in trade or commerce by, e.g., setting by
agreement the prices which the Defendants charged for vitamins, vitamin
premixes, and other vitamin products sold in the District of Columbia and
the other Class Jurisdictions;

b.

limited or reduced the production of vitamins, vitamin premixes, and other
vitamin products sold in the District of Columbia and the other Class
Jurisdictions by, e.g., allocating sales volumes among Defendants
pursuant to an agreement as alleged herein;

c.

prevented competition in the manufacture or sale of vitamins, vitamin
premixes, and other vitamin products sold in the District of Columbia and
the other Class Jurisdictions by, e.g., agreeing among themselves not to
compete over sales volumes and prices;

d.

fixed the price of vitamins, vitamin premixes, and other vitamin products
in such a way as to control or establish, at least in part, the prices paid by
consumers and the public;

e.

entered into, executed, and carried out contracts, obligations, and
agreements in which they (i) bound themselves not to sell vitamins,
vitamin premixes, and other vitamin products below a fixed price; (ii)
agreed to keep the prices of vitamins, vitamin premixes, and other vitamin
products at a fixed price; and (iii) established and settled the price of
vitamins, vitamin premixes, and other vitamin products so as to directly or
indirectly preclude a free and unrestricted competition among themselves.

Each of the above acts constitutes an unlawful trade practice or unfair or deceptive

act or practice under the antitrust and consumer protection statutes of the District of Columbia
and the antitrust and consumer protection statutes of the other Class Jurisdictions.
79.

Plaintiffs and the members of the Class were injured in their trade or business by
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reason of the unlawful acts of Defendants as alleged herein (e.g., Plaintiffs and the Class were
forced to pay higher prices for the vitamin products they purchased than they would have had to
pay if the prices charged by Defendants to their customers were the product of fair and open
competition and not of an illegal price-fixing agreement). Pursuant to the District of Columbia
Restraints of Trade Act and Consumer Protection Procedures Act and the antitrust statutes and
consumer protection statutes of the other Class Jurisdictions, Plaintiffs and the Class are entitled
to recover the full consideration paid by them, double or treble damages where appropriate,
interest on their actual damages, permanent injunctive relief, attorneys fees, costs of suit, and
such other and further relief as provided by applicable statute and as the Court may deem just,
proper, and appropriate.
80.

The combination and conspiracy consisted of a continuing agreement,

understanding, and concert of action among the conspirators, the substantial terms of which
were:

81.

a.

to fix, stabilize, and maintain prices and/or to coordinate price increases
for the sale of vitamins,-vitamin premixes, bulk vitamins, and other
vitamin products in the District of Columbia and the other Class
Jurisdictions; and

b.

to allocate the volumes of sales of, and markets for, vitamins, vitamin
premixes, bulk vitamins, and other vitamin products among the corporate
conspirators in the District of Columbia and the other Class Jurisdictions;

c.

to control the markets for vitamin premixes, for example, by agreeing to
price premixes at levels in excess of the prices offered for the component
vitamin ingredients.

For purposes of forming and carrying out the charged combination and

conspiracy, Defendants and their co-conspirators participated in covert meetings and
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conversations in which the prices, volume of sales, and markets for vitamins and vitamin
premixes were discussed and decided. Executives participating in these meetings and
discussions include Defendants John Kennedy, Robert Samuelson, Lindell Hilling, J. L. “Pete”
Fischer, and Antonio Felix. Further, for purposes of carrying out the charged combination and
conspiracy, Defendants and their co-conspirators have issued price announcements in
publications and have coordinated price quotations to customers in accordance with the
agreements reached.
82.

In the above described meetings and discussions during the period of the

conspiracy:

83.

a.

the prices and volumes of vitamins and vitamin premixes were discussed;

b.

it was agreed to increase and maintain those prices;

c.

it was agreed to allocate markets for premixes and vitamin ingredients for
such premixes;

d.

methods to conceal the agreements were discussed.

For purposes of forming and carrying out the charged combination and

conspiracy, Defendants and their co-conspirators have participated in meetings and conversations
in which it was agreed to allocate among the corporate conspirators the volumes of sales of, and
markets for, vitamins, vitamin premixes, bulk vitamins, and other vitamin products, to be sold by
each corporate conspirator in the District of Columbia and the other Class Jurisdictions. The
conspiracy divided and allocated such markets by region and by vitamin and was implemented
by Defendants’ and their co-conspirators’ executives and United States marketing managers
acting under instructions from European executives.
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84.

For example, for purposes of carrying out the charged combination and

conspiracy, co-conspirator Roche and Defendant Lonza agreed that Lonza would control the
markets for vitamin B-3/niacin with Roche as a customer, and Lonza would withdraw from
selling biotin/vitamin H in 1995 or 1996. In addition, Defendants and their co-conspirators have
allocated the United States markets for B-4/choline chloride to sellers other than their co
conspirator BASF, and the B-4/choline chloride markets in Europe have been allocated to their
co-conspirator BASF.
85.

Defendants have issued price announcements in accordance with the agreements,

and have participated in meetings and conversations to monitor and enforce adherence to the
agreed-upon prices and sales volumes.
B.

Additional Facilitating Practices and Agreements
86.

For purposes of carrying out the charged combination and conspiracy, Defendants

and their co-conspirators have rigged bids for contracts to supply vitamins, vitamin premixes,
bulk vitamins, and other vitamin products.
87.

For purposes of forming and carrying out the charged combination and

conspiracy, Defendants and their co-conspirators have exchanged information on the volumes of
sales of vitamins, vitamin premixes, bulk vitamins, and other vitamin products and chemicals
necessary for the production of vitamins in order to monitor and enforce adherence to the agreedupon prices, sales volumes and market allocations in the District of Columbia and the other Class
Jurisdictions.
C.

The Impermissible Effect on Relevant Markets and Injury to Plaintiffs
88.

Prior to the late 1980's, the markets for vitamins and vitamin premixes were
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characterized by low prices and competition. Since then, the markets for several vitamins sold
by Defendants, such as vitamins A, B, and E and vitamin premixes, have been characterized by
stability and steady price increases. Due to Defendants’ price fixing and market allocation
activity, steady price increases have taken place in these products despite fluctuations in the costs
of production. As a result of Defendants’ conduct, prices have been maintained at all time high
levels since the beginning of the decade.
89.

For many years, vitamin prices have not followed the laws of supply and demand

existing in a competitive market. Price reductions, for example, have not followed increases in
supply. For example, due to Defendants’ price fixing, market allocation, and other anti
competitive conduct, prices increased even as new supply and production came on the market.
90.

The foregoing conduct has continued until at least 1998. Executives of Roche,

BASF, and Rhone-Poulenc continued until at least then to discuss the fixing of prices and the
allocation of markets, both by telephone, wireline and cellular, and in person. The purpose of
these communications has been to anticompetitively manage and control the markets for
vitamins, vitamin premixes, and other vitamin products.
91.

This combination and conspiracy has had the following effects, among others:
a.

the prices of vitamins, vitamin premixes, bulk vitamins, and other vitamin
products indirectly purchased by Plaintiffs and the Class have been fixed,
raised, maintained and stabilized at artificial and non-competitive levels;

b.

the prices of substitute products for vitamins, vitamin premixes, bulk
vitamins, and other vitamin products indirectly purchased by Plaintiffs and
the Class have been fixed, raised, maintained and stabilized at artificial
and non-competitive levels;

c.

indirect purchasers of vitamins, vitamin premixes, bulk vitamins, and
other vitamin products, including Plaintiffs and members of the Class,
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have been deprived of free and open competition in the purchase of
vitamins, vitamin premixes, bulk vitamins, and other vitamin products;

92.

d.

competition in the sale of vitamins, vitamin premixes, bulk vitamins, and
other vitamin products has been restrained;

e.

indirect purchasers of vitamin products have paid higher prices than they
would have in the absence of the conspiracy alleged herein.

During the period covered by this Complaint, members of the Class have

purchased millions of dollars of vitamins, vitamin premixes, and bulk vitamin products from
Defendants. By reason of the alleged violations of the antitrust and consumer protection laws,
Class members have paid millions of dollars more for vitamin products and substitute products
than they would have paid in the absence of the illegal combination and conspiracy and, as a
result, have been injured in their business and property and have suffered damages in an amount
presently undetermined.
D.

Fraudulent Concealment and Equitable Tolling
93.

Plaintiffs did not discover, and could not discover through the exercise of

reasonable diligence, the existence of the claims sued upon until recently because Defendants
and their co-conspirators actively, intentionally, and fraudulently concealed the existence of the
combination and conspiracy from Plaintiffs by, among other things, one or more of the following
affirmative acts, including acts in furtherance of the conspiracy:
a.

covert meetings in the Black Forest in Germany and elsewhere in which
the prices, volumes of sale and markets for vitamins and vitamin premixes
were discussed and decided;

b.

allocating secretly among themselves either customers or contracts for the
sale of vitamins, vitamin premixes and vitamin products as compensation
for losing customers or markets;
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94.

c.

intentionally bidding with inflated bids for customer business to make
other bids appear legitimate;

d.

intentionally bidding purportedly on a competitive basis when such bid
was the result of collusion;

e.

offering improper payments to witnesses who have knowledge of the
existence of the conspiracy to keep them silent, including a rejected offer
of increased orders by telephone in 1997 to a individual in Arkansas by a
BASF buyer in exchange for his silence about the conspiracy;

f.

instructing members of the conspiracy at the above described meetings not
to divulge the existence of the conspiracy to others not in the conspiracy;

g.

confining the anticompetitive, unlawful plan to a small number of people
and key officials at each Defendant company;

h.

avoiding either references in documents, or the creation of documents
otherwise created in the ordinary course of Defendants’ businesses,
regarding conduct which would constitute an antitrust violation or
anticompetitive act.

Any applicable statutes of limitation have been tolled by Defendants’ affirmative

acts of fraudulent concealment and continuing misrepresentations. Through such affirmative acts
of fraudulent concealment, Defendants have been able to conceal from Plaintiffs and the public
the truth about charging artificially inflated prices for their vitamin products, thereby tolling the
running of the applicable statutes of limitation.
95.

Because of the self-concealing nature of Defendant’s actions, and their affirmative

acts of concealment, Plaintiffs assert the tolling of any applicable statutes of limitations affecting
their claims.
VII.

FIRST CAUSE OF ACTION

(Violations of the District of Columbia Restraints of Trade Act and
the Antitrust Laws of the other Class Jurisdictions)
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96.

Plaintiffs hereby adopt and incorporate by this reference each of the preceding

paragraphs as if fully set forth herein.
97.

The acts committed by Defendants as alleged herein constitute an unlawful

contract, combination, or conspiracy under the District of Columbia Restraints of Trade Act,
D.C. Code §§ 28-4501 etseq., and under the antitrust statutes of the following jurisdictions:

98.

Arizona:

A.R.S. §44-1402, etseq:,

Alabama:

Ala. Code §§6-5-60 and 8-10-1;

California:

Cal. Bus & Prof. Code §§ 16720, 16726 and 16750;

Kansas:

Kan. Stat. Ann. § 50-101, etseq:,

Maine:

10 Me. Rev. Stat. Ann. §1101, et seq.;

Michigan:

M.C.L.A. § 445.772, etseq:,

Minnesota:

Minn. Stat. Ann §§ 325D.57 and 325D.58;

New Mexico:

N.M. Stat. Ann. §57-1-1, et seq:,

New York:

N.Y. Gen. Bus. § 340, et seq:,

North Carolina:

N.C. Gen. Stat. §75-1, etseq:,

North Dakota:

N.D. Cent. Code §51-08.1-08;

South Dakota:

S.D. Codified Laws Ann. §§37-1-14.3, 37-1-33;

Tennessee:

T.C.A. § 47-25-101, et seq.;

West Virginia:

W.Va Code §47-18-1, etseq:,

Wisconsin:

Wis. Stat. § 133.01 etseq:,

With respect to purchases of Defendants’ vitamin products in the State of
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Arizona, Defendants’ conduct alleged herein violates Ariz. Rev. Stat. §§ 44-1402, et seq. As a
result of this violation, Class members who purchased Defendants’ vitamin products in the State
of Arizona during the Class Period were injured in their business and property in an amount
presently undetermined.
99.

With respect to purchases of Defendants’ vitamin products in the State of

Alabama, Defendants’ conduct alleged herein violates Ala. Code §§6-5-60 and 8-10-1. As a
result of this violation, Class members who purchased Defendants’ vitamin products in the State
of Alabama during the Class Period were injured in their business and property in an amount
presently undetermined.
100.

With respect to purchases of Defendants’ vitamin products in the State of

California, Defendants’ conduct alleged herein violates Cal. Bus & Prof. Code §§ 16720,16726
and 16750. As a result of this violation, Class members who purchased Defendants’ vitamin
products in the State of California during the Class Period were injured in their business and
property in an amount presently undetermined.
101.

With respect to purchases o f Defendants’ vitamin products in the State of Kansas,

Defendants’ conduct alleged herein violates Kan. Stat. Ann. § 50-101, et seq. As a result of this
violation, Class members who purchased Defendants’ vitamin products in the State of Kansas
during the Class Period were injured in their business and property in an amount presently
undetermined.
102.

With respect to purchases of Defendants’ vitamin products in the State of Maine,

Defendants’ conduct alleged herein violates 10 Me. Rev. Stat. Ann. §§ 1101, et seq. As a result
of this violation, Class members who purchased Defendants’ vitamin products in the State of
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Maine during the Class Period were injured in their business and property in an amount presently
undetermined.
103.

With respect to purchases of Defendants’ vitamin products in the State of

Michigan, Defendants’ conduct alleged herein violates M.C.L.A. § 445.772, etseq. As a result
of this violation, Class members who purchased Defendants’ vitamin products in the State of
Michigan during the Class Period were injured in their business and property in an amount
presently undetermined.
104.

With respect to purchases of Defendants’ vitamin products in the State of

Minnesota, Defendants’ conduct alleged herein violates Minn. Stat. Ann §§ 325D.57 and
325D.58. As a result of this violation, Class members who purchased Defendants’ vitamin
products in the State of Minnesota during the Class Period were injured in their business and
property in an amount presently undetermined.
105.

With respect to purchases of Defendants’ vitamin products in the State of New

Mexico, Defendants’ conduct alleged herein violates New Mexico Stat. §§ 57-1-1 et seq. As a
result of this violation, Class members who purchased Defendants’ vitamin products in the State
of New Mexico during the Class Period were injured in their business and property in an amount
presently undetermined.
106.

With respect to purchases of Defendants’ vitamin products in the State of New

York, Defendants’ conduct alleged herein violates N.Y. Gen. Bus. § 340, et seq. As a result of
this violation, Class members who purchased Defendants’ vitamin products in the State of New
York during the Class Period were injured in their business and property in an amount presently
undetermined.
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107.

With respect to purchases of Defendants’ vitamin products in the State of North

Carolina, Defendants’ conduct alleged herein violates N.C. Gen. Stat. §75-1, et seq. As a result
of this violation, Class members who purchased Defendants’ vitamin products in the State of
North Carolina during the Class Period were injured in their business and property in an amount
presently undetermined.
108.

With respect to purchases of Defendants’ vitamin products in the State of North

Dakota, Defendants’ conduct alleged herein violates N.D. Cent. Code §51-08.1-08. As a result
of this violation, Class members who purchased Defendants’ vitamin products in the State of
North Dakota during the Class Period were injured in their business and property in an amount
presently undetermined.
109.

With respect to purchases of Defendants’ vitamin products in the State of South

Dakota, Defendants’ conduct alleged herein violates S.D. Codified Laws Ann. §§37-1-14.3, 371-33. As a result of this violation, Class members who purchased Defendants’ vitamin products
in the State of South Dakota during the Class Period were injured in their business and property
in an amount presently undetermined.
110.

With respect to purchases of Defendants’ vitamin products in the State of

Tennessee, Defendants’ conduct alleged herein violates T.C.A. § 47-25-101, et seq.. As a result
of this violation, Class members who purchased Defendants’ vitamin products in the State of
I

Tennessee during the Class Period were injured in their business and property in an amount
presently undetermined.
111.

With respect to purchases of Defendants’ vitamin products in the State of West

Virginia, Defendants’ conduct alleged herein violates W. Va Code §47-18-1, et seq. As a result
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of this violation, Class members who purchased Defendants’ vitamin products in the State of
West Virginia during the Class Period were injured in their business and property in an amount
presently undetermined.
112.

With respect to purchases of Defendants’ vitamin products in the State of

Wisconsin, Defendants’ conduct alleged herein violates Wis. Stat. § 133.01 et seq. As a result of
this violation, Class members who purchased Defendants’ vitamin products in the State of
Wisconsin during the Class Period were injured in their business and property in an amount
presently undetermined.
113.

With respect to purchases of Defendants’ vitamin products in the District of

Columbia, Defendants’ conduct alleged herein violates D.C. Code §§ 28-4501 et seq. As a result
of this violation, Class members who purchased Defendants’ vitamin products in the District of
Columbia during the Class Period were injured in their business and property in an amount
presently undetermined.
114.

Pursuant to D.C. Code §§ 28-4508, et seq., and, where applicable, pursuant to the

antitrust statutes of the other Class Jurisdictions, Plaintiffs demand treble damages and restitution
from the Defendants of all monies illegally acquired by them as a result of the unlawful conduct
alleged herein as provided by law in each of the Class Jurisdictions.
VIII.

SECOND CAUSE OF ACTION

(Violation of the District of Columbia Consumer Protection Procedures Act
and the Consumer Protection Statutes of the other Class Jurisdictions)
115.

P laintiffs

hereby adopt and incorporate by this reference each of the preceding

paragraphs as if fully set forth herein.
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116.

Defendants’ actions described herein constitute unfair or deceptive trade practices

substantially affecting trade or commerce in the District of Columbia in violation of the
Consumer Protection Procedures Act, D.C. Code §§ 28-3901 et seq..
117.

Defendants’ conduct as alleged herein also constitutes violations of the consumer

protection laws of the following Class Jurisdictions:
California:

Cal. Bus & Prof. Code §17200, et seq.

Florida:

Florida Statutes §501.204, et seq.

Kansas:

Kan. Stat. Ann. §50-626(b)

Maine:

5 Me. Rev. Stat. Ann. §207;

Michigan

M. C.L.A. § 19.418(3)

Minnesota

Minn. Stat. Ann. §325D.44

New Mexico:

N. M. Stat. Ann. §57-12-3;

North Dakota: N.D. Cent. Code §51-15-02:
South Dakota: S.D. Codified Laws Ann. §37-26-6;

118.

Tennessee:

T.C.A.§ 47-18-101, et seq.

West Virginia:

W. Va. Code §46A-6-104 and §47-11 A-l, et seq.

By reason of the violations of the District of Columbia Consumer Protection

Procedures Act, D.C. Code §§ 28-3901, et seq., and the consumer protection acts of the other
Class Jurisdictions, Plaintiffs and other members of the Class have been injured because, among
other reasons, they have paid more for Defendants’ vitamin products than they would have paid
in the absence of the Defendants’ unfair or deceptive trade practices.
119.

The illegal conduct alleged in this complaint is continuing.
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120.

Consumers in the District of Columbia and in the other Class Jurisdictions have

been and will continue to be injured in their business and property by Defendants’ unfair and
deceptive trade practices.
121.

Pursuant to D.C. Code §§ 28-3905 and, where applicable, pursuant to the

consumer protection statutes of the other Class Jurisdictions, Plaintiffs demand treble damages
and restitution from the Defendants of all monies illegally acquired by them as a result of the
unlawful conduct alleged herein.
IX.

THIRD CAUSE OF ACTION
(Unjust Enrichment)

122.

Plaintiffs repeat and reallege each of the foregoing allegations as if fully set forth

123.

Defendants have benefitted from their illegal restraints of trade and acts which

herein.

lessen or tend to lessen competition through the overpayment by Plaintiffs and the Class for
Defendants’ vitamin products.
124.

It would be inequitable for the Defendants to be permitted to retain any of the

Plaintiffs’ and other purchasers’ overpayment for Defendants’ vitamin products derived from

their unfair or deceptive trade practices.
125.

Plaintiffs demand that Defendants disgorge all such monies acquired through

Defendants’ illegal and inequitable conduct.
X.

PRAYER FOR RELIEF

WHEREFORE, Plaintiffs pray for judgment against all Defendants, jointly and severally,
as follows:
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a.

certifying this action to proceed as a class action pursuant to Super. Ct. Civ .R. 23,
and direct that reasonable notice be given to members of the Class;

b.

declaring that the violations alleged herein constitute an unlawful contract,
combination, and conspiracy in restraint of trade or commerce, in violation of the
District of Columbia Restraints of Trade Act, D.C. Code §§ 28-4501, et seq., and
the antitrust laws of the other Class Jurisdictions, and that the Court award
Plaintiffs and the Class (i) actual damages in an amount to be proved at trial as a
result of the wrongful conduct alleged, plus interest and costs; (ii) treble damages
pursuant to D.C. Code §§ 28-4508 and, where appropriate, the antitrust laws of
the other Class Jurisdictions; and (iii) all other damages available under the
antitrust statutes of the other Class Jurisdictions;

c.

declaring that the concerted violations alleged herein constitute a deceptive or
unlawful trade practice in violation of the District of Columbia Consumer
Protection Procedures Act, D.C. Code §§ 28-3901, et seq., and the consumer
protection statutes of the other Class Jurisdictions, and that the Court award
Plaintiffs and the Class (i) actual damages in an amount to be proved at trial as a
result of the wrongful conduct alleged, plus interest and costs; (ii) treble damages
pursuant to D.C. Code §§ 28-3905 and, where appropriate, the consumer
protection statutes of the other Class Jurisdictions; and (iii) all other damages
available under the consumer protection statutes of the other Class Jurisdictions;

d.

declaring that the violations alleged herein resulted in the unjust enrichment of
Defendants, and that such Defendants be required to disgorge to Plaintiffs and the
Class all amounts by which they have been unjustly enriched, plus interest and
costs;

e.

granting Plaintiffs and the Class the costs of prosecuting this action together with
interest and reasonable attorney’s fees;

f.

entering joint and several judgments in favor of Plaintiffs and the Plaintiff Class
against the Defendants, and each of them in accordance with a-e above;

g.

permanently enjoining Defendants from continuing to engage in the unlawful
conduct described herein; and

h.

granting such other, further and general relief as this Court may deem just and
proper.
XL

.JURY DEMAND

Plaintiffs demand trial by jury on all claims for which they are entitled to a jury trial.
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DATED:
Respectfully submitted,

Timothy D. Battin
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